Oculis to Feature Privosegtor’s Neuroprotective Potential and Ongoing PIONEER Program at APOIS Congress and CNS Summit
Key Highlights
- ➤ACUITY Phase 2 showed improved visual function in acute optic neuritis
- ➤ACUITY preserved retinal anatomy and reduced blood neurofilament levels
- ➤PIONEER-1 registrational trial is enrolling acute-onset optic neuritis patients
- ➤Oculis anticipates IND clearance for acute multiple sclerosis relapses in Q4 2026
- ➤Privosegtor received FDA Breakthrough Therapy and EMA PRIME designations
Expert Statements
Riad Sherif, Chief Executive Officer at Oculis
“Oculis will sponsor the 6(th) Asia-Pacific Ophthalmic Innovation Society Congress, where Riad Sherif, M.D., Chief Executive Officer, will present an overview of Privosegtor and the PIONEER registrational program.”
Aaron Tansy, Vice President, Development Franchise Head, Neurology at Oculis
“Aaron Tansy, M.D., Vice President, Development Franchise Head, Neurology at Oculis, on behalf of the authors, will present Phase 2 ACUITY data at the CNS Summit on November 2(nd) and 3(rd).”
Positive Phase 2 ACUITY trial findings support Privosegtor’s potential to deliver a first-in-class neuroprotective treatment for patients with optic neuritis and beyond
ZUG, Switzerland, October 29(th), 2026 -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis”), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical needs in neuro-ophthalmology and ophthalmology, today announced upcoming presentations highlighting Privosegtor’s neuroprotective potential and its ongoing development in optic neuritis at the 6th Asia-Pacific Ophthalmic Innovation Society Congress and the CNS Summit.
Get started
Create a free account to read the full story.